[go: up one dir, main page]

MA44671A - Associations et méthodes comprenant un inhibiteur d'ensemble capside - Google Patents

Associations et méthodes comprenant un inhibiteur d'ensemble capside

Info

Publication number
MA44671A
MA44671A MA044671A MA44671A MA44671A MA 44671 A MA44671 A MA 44671A MA 044671 A MA044671 A MA 044671A MA 44671 A MA44671 A MA 44671A MA 44671 A MA44671 A MA 44671A
Authority
MA
Morocco
Prior art keywords
capside
associations
methods including
set inhibitor
inhibitor
Prior art date
Application number
MA044671A
Other languages
English (en)
Inventor
Jan Martin Berke
Osvaldo Flores
George Hartman
Klaus Klumpp
Man Lu Lam
Original Assignee
Janssen Sciences Ireland Uc
Novira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc, Novira Therapeutics Inc filed Critical Janssen Sciences Ireland Uc
Publication of MA44671A publication Critical patent/MA44671A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA044671A 2016-04-15 2017-04-14 Associations et méthodes comprenant un inhibiteur d'ensemble capside MA44671A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662323251P 2016-04-15 2016-04-15
US201662421035P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
MA44671A true MA44671A (fr) 2019-02-20

Family

ID=59298511

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044671A MA44671A (fr) 2016-04-15 2017-04-14 Associations et méthodes comprenant un inhibiteur d'ensemble capside

Country Status (13)

Country Link
US (2) US10441589B2 (fr)
EP (2) EP3848026A1 (fr)
JP (1) JP2019511542A (fr)
KR (1) KR20180129943A (fr)
CN (1) CN109640980A (fr)
AU (1) AU2017248828A1 (fr)
BR (1) BR112018071048A2 (fr)
CA (1) CA3021068A1 (fr)
IL (1) IL262378A (fr)
MA (1) MA44671A (fr)
MX (2) MX2018012557A (fr)
SG (2) SG10202011827YA (fr)
WO (1) WO2017181141A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015214096B2 (en) 2014-02-05 2021-02-11 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US10077239B2 (en) * 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
JP6801004B2 (ja) 2016-12-19 2020-12-16 パイオニア株式会社 発光装置及び発光システム
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
MA52019A (fr) * 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
CA3132170A1 (fr) * 2019-04-18 2020-10-22 Michael BIERMER Polytherapie pour le traitement d'une infection par le virus de l'hepatite b
AU2020269897A1 (en) 2019-05-06 2021-10-14 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2020255012A1 (fr) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (hbv) et de modulateurs d'assemblage de capsides qui sont des dérivés de sulfonamide
CA3140707A1 (fr) 2019-06-18 2020-12-24 Helen Horton Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de quinazoline
TW202146008A (zh) * 2020-02-27 2021-12-16 愛爾蘭商健生科學愛爾蘭無限公司 Ｈｂｖ的治療
WO2021178612A1 (fr) * 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
JP2023547150A (ja) * 2020-11-05 2023-11-09 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド カプシドタンパク質阻害剤及びヌクレオシド類似体を含む医薬組合せ

Family Cites Families (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
EP0135545A1 (fr) 1983-02-19 1985-04-03 Beecham Group Plc Derives anylides et benzamides d'azabicycloalkyle
JPS62142164A (ja) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd ４，５−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤
IN164880B (fr) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (fr) 1987-03-13 1997-07-29 Rikuo Nasu Derives de l'imidazole et compositions a base de ces derives pour l'elimination d'organismes nuisibles
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
ATE235470T1 (de) 1994-05-27 2003-04-15 Black James Foundation Gastrin- und cck-antagonisten
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
JP2000512646A (ja) 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７受容体アンタゴニストとしてのスルホンアミド誘導体
WO1998023285A1 (fr) 1996-11-29 1998-06-04 Smithkline Beecham Plc Utilisation d'une combinaison de penciclovir et d'alpha-interferon pour preparer un medicament servant a traiter l'hepatite b
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
EP1741424B1 (fr) 1997-08-11 2018-10-03 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
ATE413386T1 (de) 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulatoren
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
ATE312081T1 (de) 1999-01-15 2005-12-15 Altana Pharma Ag 6-phenylphenanthridine mit pde-iv hemmender wirkung
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
ATE382351T1 (de) 1999-08-10 2008-01-15 Univ Oxford Langkettige n-alkyl verbindungen und deren oxa- derivate zur verwendung als anitvirale mittel
WO2001019788A2 (fr) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
EP1738749A1 (fr) 1999-12-23 2007-01-03 Pfizer Products Inc. Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorées
AU2018301A (en) 1999-12-28 2001-07-24 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2882801A (en) 2000-01-28 2001-08-07 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (fr) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Dérivés de sulfonamide pharmaceutiquement actifs comportant des groupes lipophiles ainsi que ionisables comme inhibiteurs de protéine junkinases
WO2002051410A2 (fr) 2000-12-22 2002-07-04 Akzo Nobel N.V. Derives de phenylthiazole et thiazoline et leur utilisation comme antiparasites
EP1357123B8 (fr) 2000-12-27 2006-02-01 Dainippon Sumitomo Pharma Co., Ltd. COMPOSES DE CARBAPENEM, médicament et antibactérien les comprenant , et leurs usages.
WO2002064618A2 (fr) 2001-02-09 2002-08-22 Massachusetts Institute Of Technology Methodes d'identification d'agents mediant une agregation de polypeptides
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
JP4220249B2 (ja) 2001-04-19 2009-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 サイクリックアミジン誘導体
WO2003000295A2 (fr) 2001-06-21 2003-01-03 Pfizer Products Inc. Formulations auto-emulsifiantes d'inhibiteurs de la proteine de transfert du cholesterol esterifie (cetp)
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (de) 2001-07-25 2003-02-13 Degussa Verfahren zur Herstellung von modifiziertem Ruß
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EP1448560B1 (fr) 2001-11-20 2005-06-15 Eli Lilly And Company AGONISTES beta 3 A BASE D'OXINDOLE 3-SUBSTITUE
EP1469829B1 (fr) 2002-02-01 2016-01-27 Bend Research, Inc Formes posologiques a liberation immediate, contenant des dispersions medicamenteuses solides
CN1787808A (zh) 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
CA2472028C (fr) 2002-02-01 2010-03-30 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
AU2003242127A1 (en) 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
CN1678311A (zh) 2002-06-27 2005-10-05 诺沃挪第克公司 用作治疗剂的芳基羰基衍生物
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
WO2004010943A2 (fr) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Benzanilides substitues utilises comme modulateurs du recepteur ccr5
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JP4399862B2 (ja) 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
BR0314059A (pt) 2002-09-06 2005-07-05 Janssen Pharmaceutica Nv Compostos heterocìclicos
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
EP1590327A1 (fr) 2002-12-23 2005-11-02 Millennium Pharmaceuticals, Inc. Inhibiteurs du ccr8
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
ATE524452T1 (de) 2003-03-27 2011-09-15 Cytokinetics Inc Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen.
WO2004099192A2 (fr) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Acides carboxyliques substitues par des heterocycles
EP1620094A4 (fr) 2003-05-06 2010-04-28 Glaxosmithkline Llc Nouveaux composes chimiques
PE20050555A1 (es) 2003-05-13 2005-07-19 Schering Corp Compuestos con puente n-arilsulfonilpiperidina como inhibidores de la gamma-secretasa
WO2005007621A2 (fr) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Inhibiteurs de ligase d'ubiquitine
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
US20060122173A1 (en) 2003-06-06 2006-06-08 Jakob Busch-Petersen Il-8 receptor antagonists
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2005087217A1 (fr) 2004-03-05 2005-09-22 The General Hospital Corporation Compositions et procedes pour moduler l'interaction entre des polypeptides
JP2007536344A (ja) 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
JP2008501009A (ja) 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 性能を高めた医薬組成物
WO2005115374A1 (fr) 2004-05-29 2005-12-08 7Tm Pharma A/S Ligands du recepteur crth2 utilises a des fins therapeutiques
CA2571058A1 (fr) 2004-06-22 2006-01-05 Schering Corporation Ligands des recepteurs cannabinoides
HUE041596T2 (hu) 2004-07-30 2019-05-28 Exelixis Inc Pirrol származékok mint gyógyászati szerek
DE102004042441A1 (de) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2005278959A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
RU2007114080A (ru) 2004-10-13 2008-11-27 Вайет (Us) N-бензилсульфонил-замещенные аналоги анилинопиримидина
EP2275412A1 (fr) 2004-10-19 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Dérivés d'indole et de benzimidazole
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
UY29300A1 (es) 2004-12-22 2006-07-31 Astrazeneca Ab Compuestos quimicos
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
FI117653B (fi) 2005-02-21 2006-12-29 Eigenor Oy Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla
MX2007012220A (es) 2005-04-06 2007-12-06 Mallinckrodt Inc Formulacion farmaceutica de liberacion por pulsos a base de matriz.
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2006128172A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Procede pour traiter des troubles auto-immuns regules par des lymphocytes b
WO2006128129A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Traitement anticancereux
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
RU2008128452A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
WO2007075702A2 (fr) 2005-12-21 2007-07-05 Schering Corporation Traitement de la steatose hepatique non alcoolique au moyen d'agents hypocholesterolemiants et/ou dun agoniste inverse/antagoniste du recepteur h3
EP1981849A1 (fr) 2005-12-29 2008-10-22 LEK Pharmaceuticals D.D. Composes heterocycliques
CN101437824B (zh) 2006-05-04 2013-03-13 肝炎与病毒研究所 用于慢性肝炎病毒治疗的乙型肝炎病毒抗原分泌的抑制剂
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
WO2008022171A1 (fr) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Procédés d'utilisation de composés d'arylsulfonyle efficaces en tant qu'inhibiteur d'époxyde hydrolase soluble
JP2010505834A (ja) 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド系逆転写酵素阻害剤
US8372836B2 (en) 2006-10-17 2013-02-12 Bend Research, Inc. Spray dried formulation
EP2091527B1 (fr) 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Analogues de sulfure, sulfoxyde et sulfone de chalcone, leurs dérivés et leurs utilisations thérapeutiques
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
JP2008184403A (ja) 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
EP2137162B1 (fr) 2007-03-15 2018-08-01 Novartis AG Composés organiques et leurs utilisations
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
BRPI0811516A2 (pt) 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase
CN101328169B (zh) 2007-06-18 2011-05-25 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
CA2695071A1 (fr) 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag Utilisation de derives de benzamide pour le traitement de troubles du snc
CN101429166B (zh) 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
WO2009061856A1 (fr) 2007-11-09 2009-05-14 The Salk Instituite For Biological Studies Inhibiteurs non nucléosidiques de la transcriptase inverse
EP2219646A4 (fr) 2007-12-21 2010-12-22 Univ Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2009146013A1 (fr) 2008-03-31 2009-12-03 Georgetown University Inhibiteurs de phosphatase de chaîne légère de myosine
JP5501226B2 (ja) 2008-04-24 2014-05-21 Ｍｓｄ株式会社 アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
EP2317849A4 (fr) 2008-06-26 2011-11-02 Inspire Pharmaceuticals Inc Procédé permettant de traiter des maladies pulmonaires par des composés inhibiteurs de rho kinase
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
EP2321268A2 (fr) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryle aminotétralines
WO2010027996A1 (fr) 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Dérivés d’imino sucre présentant une activité antivirale puissante et une toxicité réduite
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (fr) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Inhibiteurs de la lipase destinés à être utilisés dans le traitement de l’obésité
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
EP2400969A4 (fr) 2008-12-04 2012-05-16 Inspire Pharmaceuticals Inc Procédé pour traiter des maladies pulmonaires en utilisant des composés inhibiteurs de kinase rho
TW201036614A (en) 2008-12-30 2010-10-16 Arqule Inc Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010088000A2 (fr) 2009-02-02 2010-08-05 Angion Biomedica Corp. Composés antifibrotiques et leurs utilisations
WO2010123139A1 (fr) 2009-04-24 2010-10-28 持田製薬株式会社 Dérivé arylcarboxamide ayant un groupe sulfamoyle
CN102438984A (zh) 2009-05-19 2012-05-02 拜耳作物科学公司 杀虫用芳基吡咯啉
US9351964B2 (en) 2009-05-27 2016-05-31 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
MX336687B (es) 2009-06-30 2016-01-28 Siga Technologies Inc Tratamiento y prevencion de infecciones del virus del dengue.
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011035143A2 (fr) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Procédés et compositions pour inhiber des maladies et des états à médiation par rho
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
CN102093320B (zh) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2011088561A1 (fr) 2010-01-20 2011-07-28 University Of Manitoba Composés antiviraux et compositions
KR101791266B1 (ko) 2010-02-12 2017-10-30 엘지전자 주식회사 무선 통신 시스템에서 데이터 전송 방법 및 장치
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
WO2011112191A1 (fr) 2010-03-11 2011-09-15 Bristol-Myers Squibb Company Composés utilisables pour le traitement de l'hépatite c
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2552208A4 (fr) 2010-03-31 2014-07-09 Glaxo Group Ltd Imidazolyl-imidazoles en tant qu'inhibiteurs de kinase
PH12012502194A1 (en) 2010-05-07 2014-09-05 Glaxosmithkline Llc Indoles
US8993622B2 (en) 2010-06-11 2015-03-31 Eirium Ab Antiviral compounds
CA2801712A1 (fr) 2010-06-14 2011-12-22 Dow Global Technologies Llc Acetosuccinate d'hydroxypropylmethylcellulose avec substitution acetate et succinate amelioree
WO2011163593A2 (fr) 2010-06-25 2011-12-29 Philadelphia Health & Education Corporation D/B/A Drexel Induction d'une réponse immunitaire
BR112013001125A2 (pt) 2010-07-19 2016-05-17 Inspire Pharmaceuticals Inc compostos inibidores de rho cinase bifuncionais, composição e uso
JP2013536178A (ja) 2010-07-26 2013-09-19 ニューロセラピューティクス ファーマ， インコーポレイテッド アリールスルホンアミド誘導体、組成物、および使用方法
KR20130095263A (ko) 2010-07-27 2013-08-27 인스파이어 파마슈티컬스 인코퍼레이티드 전구약물 형태의 키나아제 저해제 화합물을 사용하여 안질환을 치료하는 방법
WO2012016133A2 (fr) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2012033956A1 (fr) 2010-09-08 2012-03-15 Mithridion, Inc. Composés et compositions améliorant la cognition, méthodes de préparation et méthodes de traitement
CN103889428A (zh) 2010-10-04 2014-06-25 肝炎与病毒研究所 乙型肝炎病毒抗原分泌的新型抑制剂
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
GB201103419D0 (fr) 2011-02-28 2011-04-13 Univ Aberdeen
BR122019023564B1 (pt) 2011-04-08 2021-06-22 Janssen Sciences Ireland Uc Formas de dosagem contendo derivados de pirimidina para o tratamento de infecções virais
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
US9399619B2 (en) 2011-07-01 2016-07-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
CA2857344C (fr) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Agents antiviraux de l'hepatite b
JP6162144B2 (ja) 2012-01-06 2017-07-19 ヤンセン・サイエンシズ・アイルランド・ユーシー ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用
US9657013B2 (en) 2012-02-29 2017-05-23 Baruch S. Blumberg Institute Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES2575398T3 (es) 2012-03-31 2016-06-28 F. Hoffmann-La Roche Ag 4-Metil-dihidropirimidinas novedosas para el tratamiento y la profilaxis de la infección por el virus de la hepatitis B
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
WO2013181584A2 (fr) 2012-06-01 2013-12-05 Guo, Ju-Tao Modulation de transcription d'adnccc du virus de l'hépatite b
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
CN104797561B (zh) 2012-08-28 2017-03-01 爱尔兰詹森科学公司 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途
SG11201501362PA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CA2881322A1 (fr) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag Heteroaryldihydropyrimidines d'acide 6-amine pour le traitement et la prophylaxie d'une infection par le virus de l'hepatite b
EP2938338A4 (fr) * 2012-12-27 2016-11-23 Univ Drexel Nouveaux agents antiviraux contre une infection par le vhb
WO2014126969A1 (fr) 2013-02-12 2014-08-21 Bend Research, Inc. Dispersions solides d'agents actifs faiblement hydrosolubles
CA2899706C (fr) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyle-arylamides et utilisation connexe comme medicaments dans le traitement de l'hepatite b
CA2901168C (fr) 2013-02-28 2020-09-22 Eisai R&D Management Co., Ltd. Derive de tetrahydroimidazo[1,5-d][1,4]oxazepine
JP6321688B2 (ja) 2013-03-07 2018-05-09 ダウ グローバル テクノロジーズ エルエルシー 低粘度の新規エステル化セルロースエーテル
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EP2970340B1 (fr) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
WO2014161888A1 (fr) 2013-04-03 2014-10-09 Janssen R&D Ireland Dérivés de n-phénylcarboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
WO2014184365A1 (fr) 2013-05-17 2014-11-20 Janssen R&D Ireland Dérivés de sulphamoylthiophénamides et leur utilisation en tant que médicaments pour le traitement de l'hépatite b
JP6533217B2 (ja) 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US9688681B2 (en) 2013-05-28 2017-06-27 Bayer Cropscience Aktiengesellschaft Heterocyclic compounds as pest control agents
JP6286031B2 (ja) 2013-05-28 2018-02-28 アストラゼネカ アクチボラグ 化合物
WO2014198880A1 (fr) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2
EP3357906B1 (fr) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Dérivés de pyrrolamide substitués de glyoxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
WO2015057945A1 (fr) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Effecteurs d'assemblage de virus de l'hépatite b
WO2015055764A1 (fr) 2013-10-18 2015-04-23 Syngenta Participations Ag Dérivés de 3-méthanimidamid-pyridine utilisés comme fongicides
US9567299B2 (en) 2013-10-23 2017-02-14 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA2928003A1 (fr) 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Derives d'azepane et procedes de traitement d'infections par le virus de l'hepatite b
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9169212B2 (en) * 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6517827B2 (ja) 2014-01-31 2019-05-22 コグニション セラピューティクス，インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法
AU2015214096B2 (en) 2014-02-05 2021-02-11 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
LT3114128T (lt) 2014-03-07 2019-03-25 F. Hoffmann-La Roche Ag Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai
AP2016009477A0 (en) 2014-03-13 2016-09-30 Univ Indiana Res & Tech Corp Hepatitis b core protein allosteric modulators
US9400280B2 (en) * 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CA2938050A1 (fr) 2014-03-28 2015-10-01 Sunshine Lake Pharma Co., Ltd. Composes dihydropyrimidine et leur application dans des produits pharmaceutiques
BR112016028000B1 (pt) 2014-05-30 2022-05-17 Qilu Pharmaceutical Co., Ltd Derivado de alça de di-hidropirimido como um inibidor de hbv
WO2016089990A1 (fr) 2014-12-02 2016-06-09 Novira Therapeutics, Inc. Composés de sulfonamide inverse à base de sulfure, alkyle et pyridyle pour le traitement du vhb
US9550779B2 (en) 2014-12-30 2017-01-24 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016149581A1 (fr) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Dérivés d'azocane et d'azonane, et méthodes de traitement d'infections provoquées par le virus de l'hépatite b
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3283472B1 (fr) 2015-04-17 2021-04-14 Indiana University Research & Technology Corporation Effecteurs d'assemblage de virus de l'hépatite b
WO2016183266A1 (fr) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10077239B2 (en) 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
EP3487492A4 (fr) 2016-07-20 2020-03-11 Eisai R&D Management Co., Ltd. Utilisation d'éribuline et d'inhibiteurs des histone désacétylase dans le traitement du cancer
CN109251212A (zh) 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
CN113557016A (zh) 2019-03-13 2021-10-26 爱尔兰詹森科学公司 衣壳组装调节剂固体配制品

Also Published As

Publication number Publication date
BR112018071048A2 (pt) 2019-05-07
JP2019511542A (ja) 2019-04-25
SG10202011827YA (en) 2021-01-28
KR20180129943A (ko) 2018-12-05
CN109640980A (zh) 2019-04-16
MX2018012557A (es) 2019-07-04
US10441589B2 (en) 2019-10-15
SG11201808949SA (en) 2018-11-29
EP3848026A1 (fr) 2021-07-14
MX2020011808A (es) 2020-12-07
WO2017181141A2 (fr) 2017-10-19
US11129834B2 (en) 2021-09-28
EP3442524A2 (fr) 2019-02-20
US20170340642A1 (en) 2017-11-30
CA3021068A1 (fr) 2017-10-19
US20190365767A1 (en) 2019-12-05
IL262378A (en) 2018-11-29
AU2017248828A1 (en) 2018-11-01
WO2017181141A3 (fr) 2018-01-11

Similar Documents

Publication Publication Date Title
MA44671A (fr) Associations et méthodes comprenant un inhibiteur d'ensemble capside
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
EP3440627A4 (fr) Débrumage et restauration d'images
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
EP3324978A4 (fr) Compositions d'oligonucléotides et méthodes associées
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
EP3693391C0 (fr) Anticorps et immunoconjugués anti-cll-1
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
MA46783A (fr) Polythérapie de type thérapie cellulaire t et inhibiteur de btk
EP3302490A4 (fr) Inhibiteurs d'autotaxine et leurs utilisations
FR3019522B1 (fr) Ensemble sustentateur amovible d'un giravion et giravion
MA43402A (fr) Composition pharmaceutique comprenant un inhibiteur puissant d'urat1
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3436467A4 (fr) Nouvelles compositions et méthodes thérapeutiques
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
MA54143A (fr) Compositions et méthodes
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
FR3030544B1 (fr) Pneumatique comprenant une composition comprenant un derive d'acrylate polyfonctionnel et un peroxyde
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
FR3030543B1 (fr) Pneumatique comprenant une composition comprenant un derive d'acrylate polyfonctionnel et un peroxyde